; (ii) 7 weeks for fiscal year 2019; (iii) 10 weeks for fiscal year 2020; (iv) 10 weeks for fiscal year 2021; and (v) 10 weeks for fiscal year 2022. (C) If, for fiscal years 2019 through 2022, the Secretary has carryover balances for monograph drug activities in excess of the number of weeks of such operating reserves specified in subparagraph B, the Secretary shall reduce such fee revenue and fees to provide for not more than the number of weeks of such operating reserves specified in subparagraph (B)(v). (D) If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5) establishing fee revenue and fees for the fiscal year involved. (3) Additional direct cost adjustment The Secretary shall, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue by an amount equal to— (A) 14,000,000 for fiscal year 2018; (B) 7,000,000 for fiscal year 2019; (C) 4,000,000 for fiscal year 2020; (D) 3,000,000 for fiscal year 2021; and (E) 3,000,000 for fiscal year 2022. (4) Annual fee setting (A) Fiscal year 2018 The Secretary shall, not later than January 31, 2018— (i) establish monograph drug facility fees for fiscal year 2018 under subsection (a)(1), based on the revenue amount for such year under subsection (b) and the adjustments provided under this subsection; and (ii) publish such fee revenue and facility fees in the Federal Register. (B) Subsequent fiscal years The Secretary shall, not later than January 31 of each fiscal year that begins after September 30, 2018, establish for each such fiscal year, based on the revenue amounts under subsection (b) and the adjustments provided under this subsection— (i) monograph drug facility fees under subsection (a)(1); (ii) monograph drug order request fees under subsection (a)(2)